Guest column : Ponzi schemes in Indian pharma sales a real problem

Last week, a PharmaAsia News story reported sales malpractices at Mumbai-based drug maker Novartis India. The article, which told of how representatives for Novartis’ market-leading diabetes treatment Galvus had fudged distributor receipts and bought back stock using their cash incentives to meet sales targets, may have shocked some. But when MedicinMan posted this article on …

Advertisement